Supriya Lifescience is currently trading at Rs. 278.45, up by 3.60 points or 1.31% from its previous closing of Rs. 274.85 on the BSE.
The scrip opened at Rs. 281.30 and has touched a high and low of Rs. 287.65 and Rs. 278.85 respectively. So far 29993 shares were traded on the counter.
The BSE group ‘B’ stock of face value Rs. 2 has touched a 52 week high of Rs. 381.70 on 03-Aug-2022 and a 52 week low of Rs. 170.05 on 27-Mar-2023.
Last one week high and low of the scrip stood at Rs. 287.65 and Rs. 252.50 respectively. The current market cap of the company is Rs. 2212.07 crore.
The promoters holding in the company stood at 68.30%, while Institutions and Non-Institutions held 13.28% and 18.43% respectively.
Supriya Lifescience has collaborated with Plasma Nutrition, Inc, a renowned United States-based company known for innovative consumer products located at Delaware. The strategic partnership involves an exclusive technology licensing agreement, granting Supriya Lifescience the sole rights for manufacturing and marketing Ingredient Optimized Protein (ioProtein) in India.
The primary purpose of this collaboration is to bring the optimized protein into the Indian market. ioProtein is a patented process (patent pending in the US) This revolutionary protein powder is designed for use as protein supplements and boasts a significant advantage, and it is highly bioavailable. This means that higher amounts of proteins are absorbed quickly by the body, providing consumers with a more effective and efficient protein supplement.
During the term of the agreement, Supriya Lifescience will lead the manufacturing and marketing of ioProtein in India. This marks the introduction of a new category of protein powders in the Indian market, and it is relatively healthier compared to other popular protein powders available through various Gyms, general stores, and digital marketing channels.
Supriya Lifescience is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development.